Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study
Luciano Ibba, Luigi Gargiulo, Ângela Alfano, Ruggero Cascio Ingurgio, Alessandra Narcisi, Antonio Costanzo, Mario Valenti
Abstract
Palmoplantar psoriasis is a subtype of psoriasis that occurs in 12-26% of patients during the natural history of the disease. Limited data are available regarding the use of biologics in psoriasis with the involvement of palms or soles. We conducted a retrospective study to assess the effectiveness of anti-Interleukin (IL)-23 and anti-IL-17 in palmoplantar psoriasis over 104 weeks. No statistically significant differences were observed between the two subgroups throughout the study period. After 52 weeks, 80.95% of patients treated with anti-IL-23 and 64.86% receiving an anti-IL-17 achieved a ppPGA of 0 or 1. No serious AEs or AEs leading to discontinuation were observed. Our findings support the effectiveness of IL inhibitors in this difficult-to-treat area.